Completed Enrollment

A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

I4V-MC-JAHW -

The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior antinuclear antibody-positive uveitis from 2 years to less than 18 years old.

Trial Summary

Age Range
2 - 17 years
Conditions the trial is for
Uveitis
What the trial is testing?
Baricitinib, Adalimumab
Could I receive a Placebo?
No
Enrollment Goal
40
Trial Dates
Oct 16, 2019 - Jul 2028
How long will I be in the trial?
The study will last about 284 weeks and may include 30 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have a diagnosis of JIA-U or chronic anterior antinuclear antibody (ANA) positive uveitis without systemic features

  • Participants must have active anterior uveitis

  • Participants must have an inadequate response or intolerance to MTX

  • Participants must be on a stable dose of corticosteroid eye drops

  • Participants and their partners must be willing to use two forms of birth control

Participants Must Not:

  • Participants must not have of any autoimmune inflammatory condition other than JIA

  • Participants must not have had eye surgery within the 3 months

  • Participants must not have an infection

  • Participants must not have hepatitis B or tuberculosis (TB)

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources